The Joseph Saveri Law Firm serves as Liaison Counsel for a certified class of Lidoderm End-Payors who have alleged antitrust violations against Endo Pharmaceuticals and Actavis, as well as their respective subsidiaries. Lidoderm is a lidocaine-containing patch typically used to treat post-shingles pain.
Plaintiffs claim that Endo and Actavis entered into an illegal pay-for-delay agreement in which Endo provided $96 million worth of Lidoderm to Actavis to keep generic lidocaine patches off the market for over a year. Endo further promised not to launch an authorized generic version of Lidoderm to compete with Actavis’ generic version for 7.5 months, which greatly undermined generic price competition. Plaintiffs allege that this anticompetitive scheme employed by Endo and Actavis amounted to an unlawful reverse payment that caused plaintiffs to pay higher prices for Lidoderm.
On April 3, 2014, the Judicial Panel on Multidistrict Litigation transferred numerous Lidoderm antitrust class actions to the United States District Court for the Northern District of California and assigned the cases to Judge William H. Orrick for coordinated proceedings.
On May 23, 2014, Judge Orrick appointed the Joseph Saveri Law Firm as Interim Liaison Counsel for the proposed End-Payor Class.
On November 17, 2014, the Court issued an Order largely denying Defendants’ motion to dismiss End-Payor Plaintiffs’ consolidated complaint.
On February 21, 2017, the district court granted Plaintiffs’ motion to certify a class of Lidoderm End-Payors. The court agreed that Plaintiffs’ claims are appropriate for classwide treatment. Read the opinion Here. Plaintiffs will continue to prosecute their claims against all Defendants on a classwide basis.